Geode Capital Management LLC cut its stake in Lucira Health, Inc. (NASDAQ:LHDX) by 40.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 94,673 shares of the company’s stock after selling 63,392 shares during the period. Geode Capital Management LLC owned approximately 0.25% of Lucira Health worth $628,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of LHDX. UBS Group AG purchased a new position in Lucira Health in the first quarter valued at about $37,000. Morgan Stanley purchased a new position in shares of Lucira Health during the 1st quarter worth approximately $62,000. Cypress Point Wealth Management LLC increased its stake in shares of Lucira Health by 19.7% during the 2nd quarter. Cypress Point Wealth Management LLC now owns 12,177 shares of the company’s stock worth $81,000 after purchasing an additional 2,000 shares in the last quarter. California State Teachers Retirement System purchased a new position in shares of Lucira Health during the 1st quarter worth approximately $191,000. Finally, Citadel Advisors LLC purchased a new position in shares of Lucira Health during the 1st quarter worth approximately $195,000. 42.02% of the stock is owned by institutional investors.
A number of research analysts have recently weighed in on LHDX shares. Lifesci Capital cut shares of Lucira Health from an “outperform” rating to a “market perform” rating in a research note on Friday, August 13th. Zacks Investment Research raised shares of Lucira Health from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a research note on Wednesday.
Lucira Health (NASDAQ:LHDX) last announced its earnings results on Thursday, November 11th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.04. Lucira Health had a negative net margin of 230.43% and a negative return on equity of 43.84%. Sell-side analysts anticipate that Lucira Health, Inc. will post -1.77 earnings per share for the current year.
About Lucira Health
Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.
Read More: Capital gains and your 401(k) or IRA
Want to see what other hedge funds are holding LHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lucira Health, Inc. (NASDAQ:LHDX).
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.